2 A newly identified pathology of Episodic Angioedema with Hypereosinophilia (Gleich's Syndrome) revealed by Multi-

- 3 Omics Analysis
- 4
- 5 Authors' Names and Affiliations
- 6 Tatsuya Koreeda<sup>a</sup>, Hirokazu Muraoka<sup>b</sup>,\* and Yasunori Sato<sup>c</sup>
- $\overline{7}$
- 8 <sup>a</sup> Independent Researcher, Ikawadani-cho, Kobe-shi, Hyogo 651-2113, Japan
- <sup>b</sup>CLINIC FOR Tamachi, Nagisa Terrace 4F, 3-1-32 Shibaura, Minato-ku, Tokyo 108-0023, Japan
- <sup>c</sup> Department of Preventive Medicine and Public Health, School of Medicine, Keio University
- 11 \*: correspondence
- 12
- 13 Correspondence: Hirokazu Muraoka-hirokazu\_muraoka@clinicfor.life
- 14
- 15

## 16 Abstract

17Episodic Angioedema with Eosinophilia (Gleich syndrome) is a rare disease characterized by periodic angioedema, fever. 18 and marked eosinophilia. This study aimed to elucidate the pathogenic factors of severe Gleich syndrome through 19 comprehensive multi-omics analysis, including whole genome sequencing (WGS) and RNA sequencing (RNA-seq). A 20young female patient (age: 16-20 years old) presenting with periodic high fever, extensive urticaria/eczema, and marked 21eosinophilia was diagnosed with Gleich syndrome. The symptoms were severe, showing no spontaneous remission, but 22responded to oral steroid therapy with mild resolution. WGS of the patient's blood identified high-impact pathogenic 23mutations in 16 genes, including PRDM16. RNA-seq analysis revealed differentially expressed genes (DEGs) associated 24with immune response regulation and viral defense. Combined z-score analysis of WGS and RNA-seq data highlighted 25ACE as a key gene, with its expression significantly downregulated during disease progression and recovered with 26treatment. IFNG was also identified. The findings suggest that decreased ACE expression, driven by PRDM16 mutations 27and altered IFNG expression, likely contributed to increased bradykinin levels and activation of the arachidonic acid 28cascade, resulting in the severe inflammation and angioedema characteristic of Gleich syndrome. This study highlights 29the utility of integrating WGS and RNA-seq data to uncover the molecular basis of rare diseases and provides a 30 foundation for developing therapeutic strategies for hypereosinophilic syndromes.

31

## 32 Keywords

- 33 Eosinophilia;
- 34 Gleich syndrome;
- 35 Hypereosinophilic syndrome;
- 36 Episodic Angioedema with Eosinophilia;
- 37 Whole genome sequence;
- 38 RNA sequence;
- 39 Multi-omics analysis;

40

### 42 Introduction

43Eosinophilia is defined as a condition characterized by an absolute eosinophil count in the peripheral blood exceeding 44 500 cells/µL [1,2]. Hypereosinophilia (HE) is defined as: 1) an absolute eosinophil count in the peripheral blood 45exceeding 1500 cells/µL in two blood samples taken at least 4 weeks apart; and/or 2) evidence of hypereosinophilia in 46 tissues, which includes one or more of the following criteria: a) eosinophils constituting more than 20% of the total 47nucleated cells in the bone marrow; b) an abnormally intense eosinophilic infiltration in tissues as assessed by a 48pathologist; or c) extensive deposition of eosinophil granule proteins identified by special staining techniques [3]. 49Hypereosinophilic syndrome (HES) is defined by the following criteria: 1) the criteria for HE are met, 2) there is organ 50damage caused by peripheral tissue hypereosinophilia, and 3) other conditions that could cause organ damage have been 51excluded [3]. Another syndrome associated with HE is angioedema with eosinophilia, also known as Gleich syndrome. 52This rare clinical entity was first described by Gerald Gleich in 1984 and is characterized by angioedema with marked 53eosinophilia, accompanied by fever, periodic weight gain, and urticaria [4]. Hypereosinophilic syndrome (HES) was first 54proposed as a disease concept by Hardy and Anderson in 1968, with diagnostic criteria later developed by Chusid et al. in 551975. Initially, it was considered a syndrome encompassing many conditions diagnosed primarily by exclusion. Since 56then, the causes of some conditions previously classified as HES have been clarified [5,6], but many remain unexplained. 57The same applies to hypereosinophilia (HE), including Gleich syndrome. The same is true for HE, including Gleich 58syndrome. The low prevalence of HE and HES, combined with the need to initiate treatment before confirming strict 59diagnostic criteria, has left many aspects of these diseases medically unexplored.

60 In recent years, genomic analysis technologies, including Whole Genome Sequencing (WGS), Whole Exome 61Sequencing (WES), and targeted sequencing, have gained attention as research tools for elucidating the causes and 62mechanisms of diseases [7]. By comprehensively analyzing the entire spectrum of genetic variation, this technology can 63 identify etiological genes and associated factors that are challenging to detect using conventional methods. WGS is 64 particularly effective in the study of rare diseases, where many pathologies are strongly influenced by genetic factors [8– 65 10]. In HE and HES, somatic mutations in haematopoietic cells have been investigated using targeted sequencing, as well 66 as the relationship between clonal proliferation of eosinophils and novel disease-related mutations, using WES [11,12]. 67 However, knowledge about the genetic background and mechanisms underlying the pathogenesis of HE and HES 68 remains limited, as their causes are still unknown, and few cases have been analyzed using WGS. The aim of this study 69 was to identify pathological factors in patients diagnosed with HE/Gleich syndrome of unknown etiology. We

- 70 investigated the pathological factors of idiopathic hypereosinophilia by analyzing WGS and RNA-seq data obtained from
- these patients.
- 72

#### 73 Materials and Methods

74 Patient

Patient with disease onset from April 2022 and diagnosed with severe Gleich syndrome in July 2023 was evaluated. The following clinical and laboratory information was collected: gender, age of onset, imaging evaluation of trunk organs and musculature, pathology of enlarged lymph nodes, pathology of skin lesions, peripheral blood counts including absolute

- eosinophil count, general biochemical tests, immunological tests, genetic tests, allergy tests, and parasite tests. The study
- protocol was approved by the Ethics Committees of the Clinic for Tamachi in Tokyo (approval number: CFT20230727),
- 80 Japan, and all participants provided written informed consent.
- 81

#### 82 Sample Collection

- 83 Whole blood samples (2 mL) were collected from one patient and three healthy subjects. DNA and RNA were extracted
- simultaneously from the patient's samples, which were collected at three time points: before treatment initiation, 30 days
- after treatment initiation, and 90 days after treatment initiation. The collected whole blood samples were used for
- subsequent WGS and RNA-seq analyses. The analysis workflow is provided in the Supplementary Information 1 (Figure
  S1).
- 88

## 89 WGS Processing and Sequencing

90 Nucleic acids were extracted using the NucleoSpin RNA Blood Kit and NucleoSpin RNA/DNA Buffer Set from

91 MACHEREY-NAGEL, following the manufacturer's recommended protocol. In this process, genomic DNA was eluted

92 first, followed by the extraction of total RNA. The extracted RNA was purified using the NucleoSpin RNA Clean-up XS

- 93 Kit. The quality of the nucleic acid samples was assessed using Agilent Technologies' TapeStation or BioAnalyzer. This
- 94 assessment included double-stranded DNA quantification, agarose gel electrophoresis, and purification steps. The final
- 95 quality assessment was based on the results from these instruments. Sequence libraries were prepared using Illumina's

96 TruSeq DNA PCR-Free Library Prep Kit and IDT for Illumina - TruSeq DNA UD Indexes v2. DNA was fragmented into

97 hundreds of base pairs using Covaris Acoustic Solubilisers, followed by end-repair and phosphorylation. After size

- 98 selection using magnetic beads, sequence libraries were constructed through 3' dA tailing and ligation of indexed
- 99 adaptors. Library quality was tested using Illumina's MiSeq or iSeq systems to assess library size and concentration.
- 100 Sequence analysis was performed on Illumina's NovaSeq X Plus system using the NovaSeq X Series 10B Reagent Kit

and accompanying control software. Cluster generation and sequencing were conducted with Real Time Analysis (RTA)
 v4.6.2 and bclfastq2 v2.20 software.

103

## 104 **RNA-seq Processing and Sequencing**

105 Nucleic acids were extracted from the provided samples using MACHEREY-NAGEL's NucleoSpin RNA Blood Kit, and

106 electrophoretic quantification was performed using a TapeStation or BioAnalyzer (Agilent Technologies) to assess the

107 quality and quantity of the nucleic acids. Globin-depleted RNA samples were used, and adaptor sequences were added to

108 both ends of the first-strand cDNA using the SMART method. PCR amplification was then performed using primers

109 recognizing the adaptor sequence, and the PCR products were purified with AMPure XP (Beckman Coulter). The double-

110 stranded cDNA was fragmented by a transposon-based tagging reaction, followed by the addition of adaptor sequences.

111 Next, PCR amplification was carried out using indexed primers with distinct tag sequences to create a sequencing library.

112 The quality of the library was assessed using an electrophoresis system. Reagent details for library preparation are

113 provided in the data sheet. The processed samples underwent 150 base pair paired-end sequencing analysis using the

114 NovaSeq system, and the raw data were converted to FASTQ file format using the provided software.

115

## 116 Mapping Genomic Variation and Adding Annotation Information

117Genomic mutation analysis was conducted using the DRAGEN Bio-IT Platform (Illumina). First, sequencing reads were 118mapped to the reference genome (hg38 decoy). Duplicates were marked, and these marked reads were used to identify 119candidate mutant bases, including single nucleotide substitutions and short insertions/deletions, that differ from the 120reference sequence. For multiple samples, the detection results were merged. The detected mutant bases were then 121filtered, and SnpEff and vcftools were used to assess the impact of the mutations. This assessment included comparing 122the candidate mutant bases with gene structure, predicting the impact of missense mutations (using FATHMM scores 123from dbNSFP), evaluating the mutation's frequency across populations in gnomAD and East Asian allele frequencies, 124and adding clinical significance annotations from ClinVar.

125

#### 126 Variant Filtering and Analysis Workflow

127 Variant analysis was performed using SnpSift (version 4.3t) for filtering variants. Filtering criteria were restricted to

128 variants with a total depth (DP) of 25 or greater to eliminate low-quality variants. Pathogenic SNVs were then extracted,

129 focusing on those with annotation impacts labeled as HIGH and MODERATE. The filtered variants were analyzed to

130	extract SNVs, Indels, and Structural Variants (SVs). The tools used for this analysis included AnnotSV [15],

131 wANNOVAR [16], and SNPnexus [17]. AnnotSV used VCF files filtered by total depth and extracted variants with a

132 class of 3 or higher in the ACMG guideline column. wANNOVAR focused on exonic regions, while SNPnexus excluded

133 SNPs labeled 'Benign' and 'Likely Benign' in the ClinVar column. Data tables were generated from each tool, and

134 columns without values were manually excluded upon inspection. Snowflake was utilized to examine the variants

135 directly from the VCF files: after creating the database and schema in Snowflake, the VCF files were uploaded to an

136 internal stage using SnowSQL (Version 1.2.32). The data were then loaded as semi-structured data into tables, and SQL

137 was used for filtering.

138

## 139 Mapping and Counting of Read Sequences

140 In the RNA sequencing analysis, read sequences were mapped to the human reference genome GRCh38 using Illumina's

141 NovaSeq Control Software version 1.7.5. Following mapping, quality control of the sequence data was performed using

142 Illumina's Real Time Analysis (RTA) software version 3.4.4. The resulting BCL files were converted to FASTQ format

143 using bcl2fastq2 version 2.20. For mapping, a gene definition file based on GENCODE version 39 was used,

144 incorporating detailed gene structures and annotation information. Annotation information was then added to the

145 mapping data, and expression levels were organized in a tabular format. This process was conducted using Illumina's

146 DRAGEN Bio-IT Platform version 3.7.5, with the software's default parameters applied at each step, from mapping read

147 sequences to gene expression analysis. The resulting count data were used for subsequent gene expression analyses.

148

## 149 Analysis of Established Gene Expression Levels Using RNA-Seq Data

150 Gene expression levels were analyzed using RNA-seq count data, focusing on genes labeled as 'protein\_coding' before

151 extracting Differentially Expressed Genes (DEGs). DEseq2 (Version 1.40.2) was used to identify DEGs by comparing the

152 patient samples with those of three healthy subjects. Pathway enrichment analysis and protein-protein interaction (PPI)

153 network analysis were performed on the identified DEGs. The pathway enrichment analysis was based on data from the

154 GO term and KEGG databases. GO enrichment analysis classified the DEGs into three functional groups: biological

155 processes, cellular components, and molecular functions [13]. The PPI network analysis was conducted using the

- 156 STRING database in Cytoscape, with a Confidence Score cutoff of >0.7 and a maximum of 30 additional interactors. To
- 157 identify hub genes, PPIs with a Confidence Score cutoff of >0.95 were screened, and the centrality of each gene in the

- 158 PPI network was calculated using the CentiScaPe 2.2 plugin. Heatmaps were generated using the heatmap (Version
- 159 1.0.12) package.
- 160

## 161 Integrated Variant and Gene Expression Analysis with Z-Score Standardization

- 162 After excluding low-quality variants and extracting those labeled as HIGH and MODERATE for annotation impact, the
- 163 variants were matched with RNA-seq data based on transcript ID. Variants were then filtered to include only those with
- adjusted p-values less than 0.05 and an absolute Fold Change greater than 2. The PPI network centrality score was
- 165 quantified using Centiscape 2.2. Following standardization by z-score based on adjusted p-values, absolute Fold Change,
- 166 and centrality score values, the z-score totals were calculated for each gene.
- 167

#### 168 Ingenuity Pathway Analysis of RNA-Seq Data for Upstream and Causal Regulator Identification

- 169 Ingenuity Pathway Analysis (IPA) Expression Analysis RNA-seq data files were imported into IPA, with the
- 170 log2FoldChange and padj columns mapped as 'Expr Log Ratio' and 'Expr p-value,' respectively. The analysis was
- 171 performed with a Log Ratio cut-off range of -2.32 to 2.32 and an Expr p-value cut-off of 0.05. Within the Expression
- 172 Analysis, Upstream Analysis was conducted to identify Upstream Regulators and Causal Regulators associated with the
- 173 ACE gene. For Upstream Regulators, the absolute value of the Activation Z-score for each upstream gene was mapped to
- 174 Target Molecules. For Causal Networks, intracellular pathway diagrams were created by generating networks for IFNG
- 175 genes and selecting SubCellular layouts. Disease pathway information for Angioedema and Eosinophilia was also
- 176 visualized under 'Disease and Functions'.
- 177

## 179Results 180**Clinical Findings** 181 A young female patient (age: 16-20 years old) experienced periodic episodes of fever and myalgia, with temperatures 182ranging from 38-40°C, accompanied by chills and shivering, occurring one or two times a month since April 2022. 183Around October of the same year, she developed edema, urticaria, and a generalized skin rash that left pigmentation. 184Blood tests from this period revealed markedly increased eosinophilia. During febrile episodes, the patient exhibited 185transient neutrophil predominance and significantly elevated CRP levels. Thorough examinations were conducted at the 186Clinic Fore Tamachi and Gunma University Hospital. A repeated clinical examinations revealed a total white blood cell 187 count of 19,200/µL, with an eosinophil count of 16.4% (3148/µL). Hemoglobin and platelet counts were normal limits. 188Total IgE was elevated at 504 IU/mL, but specific IgE levels for common grass and tree pollens, mites, animal 189dander, molds, and foods were within normal limits or negative. The patient, having been exposed to formalin, underwent 190a skin test for formalin sensitivity, which was negative. Screening for parasitic antibodies was also negative. 191 Rheumatoid factor, anti-nuclear antibodies, anti-ARS antibodies, MPO-ANCA, PR3-ANCA, IgG, IgA, IgM, 192C3, C4, and CH50 were all within normal limits. A peripheral blood smear examination revealed no morphological 193abnormalities. Lymphocyte surface marker tests showed the following: CD7 at 56.9%, CD3 at 44.7%, CD2 at 59.3%, 194CD4(-)CD8(+) at 9.3%, CD4(-)CD8(-) at 48.8%, CD4(+)CD8(+) at 41.2%, CD4(+)CD8(+) at 0.7%, and a CD4/CD8 195ratio of 4.19. 196Various imaging studies, including CT and MRI, did not reveal any tumorous lesions. However, imaging showed 197 enlarged axillary lymph nodes, splenomegaly, myositis centered around both shoulders, and bilateral pleural effusions. 198The sIL-2R level was elevated at 1668 U/mL, but the pathology of the enlarged lymph nodes indicated dermatopathic 199lymphadenopathy, without evidence of lymphoma or malignancy, including immunostaining results. Pathological 200examination of the skin tissue raised a suspicion of vasculitis, though this was not definitive. 201Genetic testing results were negative for the FIP1L1-PDGFRa fusion gene, PDGFB split signal, FGFR1 split signal, and 202MEFV gene mutation, with no clonal gene rearrangement detected in the T-cell receptor beta chain C $\beta$ 1. A summary of 203the clinical and laboratory information is provided below, and full test results are available in the Supplementary file 204(Supplementary Information 2). 205206

Normal Range

Gender	Female	-
Age of onset (years)	16-20	-
Age at diagnosis (years)	16-20	-
Symptoms	Angioedema Urticaria Pruritus Periodic fever Skin rash that leaves hyperpigmentation Muscle pain Splenomegaly Lymphadenopathy	-
Serum total IgM (mg/dL)	136	46 <sup>~</sup> 260
Serum total IgG (mg/dL)	1384	870 <sup>~</sup> 1700
Serum total IgA (mg/dL)	106	110~410
Serum total IgE (IU/mL)	504	≦170
Aberrant T-cell population	No	-
CRP (mg/dL)	17.2	≦0.14
sIL-2R (U/mL)	1668	157 <sup>~</sup> 474
ANA (Titer)	<1:40	<1:40
MPO-ANCA (U/mL)	<1.0	<3.5
PR3-ANCA (U/mL)	<1.0	<3.5
C3 (mg/dL)	114	86~160
C4 (mg/dL)	22	17~45
anti-ARS antibodies (Index)	<5.0	<25
EBV DNA	Not detected	-
Trunk/Maxillofacial CT	Splenomegaly Enlarged axillary lymph nodes	-
Trunk/Maxillofacial MRI	Suspected myositis around both shoulders Reactive swelling of cervical and submandibular lymph nodes Small amount of pleural effusion	-
Left axillary lymph node biopsy	Findings suggestive of dermatopathic lymphadenopathy No lymphoma or malignant findings	-
Skin biopsy	Possible vasculitis (unclear)	-
FIP1L1-PDGFRa fusion gene	Negative	-

PDGFB split signal	Negative	-
FGFR1 split signal	Negative	-
MEFV gene mutations	Negative	-

## 207 Table 1 : Characteristics of the studied patient

208

209 Based on these results and the exclusion of autoimmune and hematological disorders and secondary eosinophilia, the

210 patient was diagnosed with Episodic Angioedema with Hypereosinophilia (Gleich's Syndrome). Treatment was initiated

- in July 2023 with oral glucocorticoids (prednisolone 30 mg/day), with subsequent tapering scheduled to the current
- 212 maintenance dose of 1 mg/day. The patient achieved clinical and biological remission, generally by 30 days after
- treatment initiation and almost complete remission by 90 days.
- 214

# 215 WGS-Based Identification of Patient-Specific Genetic Variants and Associated Mutations

- 216 Patient-specific genetic variants were analyzed using WGS for diagnostic purposes. Three variant analysis tools—
- 217 AnnotSV, SNPnexus, and wANNOVAR were employed. The AnnotSV analysis was filtered to include only variants
- 218 classified with an ACMG classes of 3 or higher (Table 2). As a result, 26 variants with an ACMG class of 3 were
- 219 identified, with no variants classified as more severe. Further filtering using a LOEUF\_bin score of 0 identified deletion
- 220 mutations in the FOXO1, PRDM16, SPAST, ITSN1, and DLGAP2 genes. Mutations in FOXO1 gene have been
- 221 previously associated with rhabdomyosarcoma, a type of cancer. Variants in the PRDM16 gene have been linked to
- 222 various cancers. Mutations in the SPAST gene are known to cause neurological disorders, particularly hereditary spastic
- 223 paraplegia. However, no disease associations were identified for mutations in ITSN1 and DLGAP2 genes.

224

225

- 226
- 227

	Chr	Range	Loc	MOI	GenCC_disease	OMIM_phenotype
FOXO1	13	40661542- 40661624	CDS		-	Alveolar Rhabdomyosarcoma
PRDM16	51	3299300- 3299421	CDS	AD	dilated cardiomyopathy, familial isolated dilated cardiomyopathy, left ventricular noncompaction, left ventricular noncompaction 8	Dilated Cardiomyopathy Left ventricular noncompaction 8
PRDM16	51	3325997- 3326054	CDS	AD	dilated cardiomyopathy, familial isolated dilated cardiomyopathy, left ventricular	Dilated Cardiomyopathy
					noncompaction, left ventricular noncompaction 8	Left ventricular noncompaction 8
SPAST	2	32111248- 32111315	CDS	AD;AR	Charlevoix-Saguenay spastic ataxia, hereditary spastic paraplegia 4	Spastic paraplegia 4
ITSN1	21	33876194- 33876246	CDS		-	-
DLGAP2	28	999891-	UTR	AD	complex neurodevelopmental disorder	-
		999994				
Table 2	2: A		f SVs	Utilizir	ng AnnotSV	
Table 2	2: A		f SVs	Utilizir	ng AnnotSV	
		nalysis o			ng AnnotSV	ClinVar annotations (Table
	In the	nalysis o SNPnexus-t	based a	nalysis, the		
The analy	In the ysis id	nalysis o SNPnexus-t lentified the	based an	nalysis, the ng relevant	genes were listed as pathogenic according to 0	rs1566734), SLC4A1
The analy (rs121912	In the ysis id 2749)	nalysis o SNPnexus-t lentified the , FGFR4 (rs.	based an followi 351855	nalysis, the ng relevant ), and C1G	genes were listed as pathogenic according to 0 t mutations and corresponding genes: PTPRJ (r	rs1566734), SLC4A1 nymous SNV (A/C) was
The analy (rs121912 found at j	In the ysis id 2749) positio	nalysis o SNPnexus-t lentified the , FGFR4 (rs: on 44,260,50	oased ar followi 351855 )1 on ch	nalysis, the ng relevant ), and C1G nromosome	e genes were listed as pathogenic according to ( t mutations and corresponding genes: PTPRJ (1 ALT1C1 (rs17261572). In PTPRJ, a non-synor	rs1566734), SLC4A1 nymous SNV (A/C) was P and associated with
The analy (rs121912 found at p carcinom	In the ysis id 2749) positiona of the second	nalysis o SNPnexus-t lentified the , FGFR4 (rs2 on 44,260,50 he colon. In S	based an followi 351855 91 on ch SLC4A	nalysis, the ng relevant ), and C1G nromosome 1, a non-sy	e genes were listed as pathogenic according to 0 t mutations and corresponding genes: PTPRJ (r ALT1C1 (rs17261572). In PTPRJ, a non-synor e 17, causing an amino acid change from Q276	rs1566734), SLC4A1 nymous SNV (A/C) was P and associated with rron region at position
The analy (rs121912 found at j carcinom 177,093,2	In the ysis id 2749) positic a of tl 242 or	nalysis o SNPnexus-t lentified the , FGFR4 (rs2 on 44,260,50 he colon. In s n chromoson	based an followi 351855 01 on ch SLC4A ne 5, re	nalysis, the ng relevant ), and C1G nromosome 1, a non-sy sulting in a	e genes were listed as pathogenic according to 0 t mutations and corresponding genes: PTPRJ (r ALT1C1 (rs17261572). In PTPRJ, a non-synor e 17, causing an amino acid change from Q276 monymous SNV (G/A) was observed in the int	rs1566734), SLC4A1 nymous SNV (A/C) was P and associated with fron region at position association with cancer
The analy (rs121912 found at j carcinom 177,093,2 progressi	In the ysis id 2749) position a of the 242 on on an	nalysis o SNPnexus-t lentified the , FGFR4 (rs2 on 44,260,50 he colon. In S n chromoson d tumor cell	based an followi 351855 01 on ch SLC4A ne 5, re prolifen	nalysis, the ng relevant ), and C1G nromosome .1, a non-sy sulting in a ration. A no	e genes were listed as pathogenic according to 0 t mutations and corresponding genes: PTPRJ (r ALT1C1 (rs17261572). In PTPRJ, a non-synor e 17, causing an amino acid change from Q276 monymous SNV (G/A) was observed in the int in amino acid change to G388R, suggesting an	rs1566734), SLC4A1 nymous SNV (A/C) was P and associated with fron region at position association with cancer 21GALT1C1 at position

Gene	Chr Region	Position	SNV	AA Change	ClinVar
PTPRJ	11 coding	48123823	A/C	Q276P	Carcinoma of colon
SLC4A1	17 coding	44260501	C/T	G130R	Spherocytosis type 4
FGFR4	5 intronic	177093242	G/A	G388R	Cancer progression and tumor cell motility

C1GALT1C1 X	coding	120626774	A/T	D131E	Polyagglutinable erythrocyte syndrome
-------------	--------	-----------	-----	-------	---------------------------------------

241

# 242 Table 3: Analysis of SNVs Utilizing SNPnexus

243

244	In wANNOVAR, we identified a series of mutations across diverse genes, focusing on exonic regions (Table 4). As a
245	result, we detected two distinct frameshift mutations across multiple exons (14, 16, and 17) in the APC gene. These
246	mutations were identified as c.5400delT (p.N1800Kfs45), c.5454delT (p.N1818Kfs45), c.5399_5400del (p.N1800Kfs7),
247	and c.5453_5454del (p.N1818Kfs7), all of which were heterozygous. In OR13C8, a c.242delT mutation in exon 1
248	(p.A83Pfs6) was observed in a homozygous form, and in PCDH17, a c.237_238del mutation (p.D80Qfs78) was found in
249	exon 1, also in a homozygous form. For GSPT1, multiple frameshift mutations were identified in exon 15, including
250	c.1902_1909del (p.K635Sfs63), c.1491_1498del (p.K498Sfs63), and c.1905_1912del (p.K636Sfs*63), all of which were
251	homozygous. In MED1, two heterozygous frameshift mutations were identified in exon 17, c.3210delA (p.T1071Qfs2)
252	and c.3210_3211del (p.T1071Sfs28). In SLC35G4, synonymous SNVs c.C570T and c.C570C were detected in exon 1,
253	both heterozygous, indicating no change in the amino acid sequence of the protein (p.G190G). In exon 4 of MADCAM1,
254	a non-synonymous SNV, c.T718C (p.S240P), was identified in a heterozygous form.

Chr Position	Exon SNV	Gene	Exonic Func	Zygosity	HGVS
chr5 112176745	exon14, exon16, exon17 T/-	APC	frameshift deletion	het	c.5400delT(p.N1800Kfs*45), c.5399_5400del(p.N1800Kfs*7), c.5454delT(p.N1818Kfs*45), c.5453_5454del(p.N1818Kfs*7)
chr9 107331690	exon1 A/-	OR13C8	frameshift deletion	hom	c.242delT(p.A83Pfs*6)
chr13 58206917	exon1 T/-	PCDH17	frameshift deletion	hom	c.237_238del(p.D80Qfs*78)
chr16 11966978	exon15 A/-	GSPT1	frameshift deletion	hom	c.1902_1909del(p.K635Sfs*63), c.1491_1498del(p.K498Sfs*63), c.1905_1912del(p.K636Sfs*63)
chr1737565264	exon17 A/-	MED1	frameshift deletion	het	c.3210delA(p.T1071Qfs*2), c.3210_3211del(p.T1071Sfs*28)
chr1811610164	exon1 G/T	SLC35G4	synonymous SNV	het	c.C570T(p.G190G)
chr1811610164	exon1 G/C	SLC35G4	synonymous SNV	het	c.C570C(p.G190G)

	chr19501719 exon4 T/C MADCAM1 nonsynonymous SNV het c.T718C(p.S240P)
256	
257	Table 4: Analysis of SNVs Utilizing wANNOVAR
258	
259	Enrichment Analysis and PPI Network Analysis Utilizing RNA-seq DEGs
260	The DEGs identified from the RNA-seq data in healthy subjects and patients were further analyzed using GO
261	and KEGG pathway analyses. Upregulated genes were significantly enriched in the biological process categories of
262	'regulation of response to biotic stimulus' and 'response to virus,' as well as in the molecular function categories of
263	'DNA-binding transcription factor binding' and 'carbohydrate binding.' These genes were also significantly enriched in
264	the cellular component categories of 'endocytic vesicle' and 'specific granule' (Figure 1a and Table 5). Conversely,
265	downregulated genes were significantly enriched in the biological process categories of 'leukocyte-mediated immunity'
266	and 'cell killing,' in the molecular function categories of 'carbohydrate binding' and 'immune receptor activity,' and in
267	the cellular component categories of 'external side of plasma membrane' and 'endoplasmic reticulum lumen' (Figure 1b
268	and Table 6). Additionally, KEGG pathway analysis revealed that the most significantly enriched gene pathways were
269	those associated with the 'PI3K-Akt signaling pathway' and 'Human papillomavirus infection' (Figure 1c).
270	Next, a PPI network analysis was performed using the DEGs. In the PPI network, which consisted of 185 DEGs,
271	214 nodes and 676 edges were mapped based on protein-protein interactions with interaction scores greater than 0.7
272	(Figure 1d). Using an interaction score greater than 0.95 to identify hub genes, the most highly connected hub genes were
273	RSAD2 (degree = 9), MX1 (degree = 8), ISG15 (degree = 8), and IFI44L (degree = 7). A heatmap of the DEGs and a
274	volcano plot showing the time-series changes in each gene expression level are provided in the Supplementary
275	Information 1 (Figure S2).




Figure 1. Pathway Enrichment Analysis Utilizing GO and KEGG, and PPI Network Analysis

- 278 Pathway enrichment analysis using GO and KEGG terms, and PPI network analysis based on patient RNA-seq data. a)
- 279 Pathway enrichment analysis using GO terms for DEGs of patient-derived upregulated genes in biological process (BP),

molecular function (MF), and cellular component (CC) categories. The top 10 terms in each category are shown. b)
Pathway enrichment analysis using GO terms for DEGs of patient-derived downregulated genes. c) Pathway enrichment
analysis using KEGG terms for DEGs of patient-derived genes with variable expression. d) Pathway enrichment analysis
using GO terms for DEGs of patient-derived genes with variable expression. The vertical axis represents the percentage
of DEGs in each term. e) PPI network analysis using DEGs of patient-derived genes with variable expression. Red circles
represent nodes, and blue lines represent edges.

Category	Term	Description	Count	%	p.adjust
BP	GO:0051607	defense response to virus	47	9.69072165	8.65E-20
BP	GO:0140546	defense response to symbiont	47	9.69072165	8.65E-20
BP	GO:0009615	response to virus	53	10.9278351	3.64E-19
BP	GO:0002831	regulation of response to biotic stimulus	55	11.3402062	3.14E-18
BP	GO:0045088	regulation of innate immune response	47	9.69072165	2.09E-16
BP	GO:1903900	regulation of viral life cycle	30	6.18556701	3.82E-16
MF	GO:0003725	double-stranded RNA binding	11	2.2	0.00202485
MF	GO:0030246	carbohydrate binding	22	4.4	0.00202485
MF	GO:0046935	1-phosphatidylinositol-3-kinase regulator activity	6	1.2	0.00202485
MF	GO:0035014	phosphatidylinositol 3-kinase regulator activity	6	1.2	0.00389573
MF	GO:0140297	DNA-binding transcription factor binding	28	5.6	0.01965112
MF	GO:0005536	glucose binding	4	0.8	0.01965112
CC	GO:0042581	specific granule	17	3.37301587	0.00036595
CC	GO:0045335	phagocytic vesicle	15	2.97619048	0.00078833
CC	GO:0070820	tertiary granule	15	2.97619048	0.00329658
CC	GO:0030139	endocytic vesicle	23	4.56349206	0.00399692
CC	GO:0005811	lipid droplet	11	2.18253968	0.00446821
CC	GO:0005942	phosphatidylinositol 3-kinase complex	6	1.19047619	0.00446821

287

288 Table 5: Enrichment Analysis Using Upregulated Genes Derived from RNA-seq Data

Category	Term	Description	Count	%	p.adjust
BP	GO:0002228	natural killer cell mediated immunity	25	5.08130081	5.55E-17
BP	GO:0001909	leukocyte mediated cytotoxicity	31	6.30081301	6.45E-17
BP	GO:0042267	natural killer cell mediated cytotoxicity	24	4.87804878	1.16E-16
BP	GO:0002443	leukocyte mediated immunity	48	9.75609756	1.62E-15
BP	GO:0001906	cell killing	34	6.91056911	1.98E-15
BP	GO:0002449	lymphocyte mediated immunity	41	8.33333333	3.27E-15
MF	GO:0140375	immune receptor activity	21	4.1749503	1.84E-07
MF	GO:0015026	coreceptor activity	11	2.18687873	1.79E-05
MF	GO:0042287	MHC protein binding	9	1.78926441	0.00033639
MF	GO:0030246	carbohydrate binding	23	4.57256461	0.00033639
MF	GO:0043394	proteoglycan binding	8	1.59045726	0.00062812
MF	GO:0050840	extracellular matrix binding	9	1.78926441	0.00189935
CC	GO:0009897	external side of plasma membrane	36	7.10059172	2.48E-07
CC	GO:0044194	cytolytic granule	5	0.98619329	0.00211125
CC	GO:0045178	basal part of cell	21	4.14201183	0.00211125
CC	GO:0009925	basal plasma membrane	20	3.94477318	0.00211125
CC	GO:0005788	endoplasmic reticulum lumen	22	4.33925049	0.00211125
CC	GO:0016323	basolateral plasma membrane	18	3.55029586	0.00310627

290

291 Table 6: Enrichment Analysis Using Downregulated Genes Derived from RNA-seq Data 292 293

294

## 295 Identification of Key Genes Utilizing Z-Score Analysis

Variants from WGS data labeled as HIGH in annotation impact, along with gene expression levels from RNA-seq data
and centrality scores from PPI network analysis, were evaluated utilizing z-score analysis (Table 7). Among the Z-scores,
IFI27 had the highest value (Z-Score: 4.47619923). OAS2 (Degree: 19) and ACE (ABS\_log2FC: 9.10262032) exhibited
the highest centrality score and absolute log2 fold change, respectively. The smallest adjusted p-value was observed for

300 IFI27 (padj: 4.18E-65). The effects of the mutations were as follows: splice acceptor variant & intron variant in three 301 cases, start lost & conservative inframe deletion in one case, frameshift variant in three cases, stop lost in one case, stop 302 gained in two cases, and splice donor variant & intron variant in one case. Z-score values were utilized for GO term and 303 KEGG pathway enrichment analysis as well as PPI network analysis (Figure S3). The plots of Effect Type count values

304 for genomic variants in this patient are provided in the Supplementary Information (Figure S4).

Gene	POS	Variant	Effect	Degree	ABS_log2FC	2 padj	Z_Score
IFI27	14:94105764	G/T	splice_acceptor_variant& intron_variant	14	7.22991464	4.18E-65	4.47619973
IFI27	14:94115784	TGGCCAT GGC/T	start_lost& conservative_inframe_deletion	14	7.22991464	4.18E-65	4.47619973
IFI44	1:78662885	G/GT	frameshift_variant	18	3.62858894	1.20E-30	3.63485564
OAS2	12:113010483	A/G	stop_lost	19	2.51335138	7.25E-23	3.33028482
EPSTI1	13:42888298	T/TTCAGG	frameshift_variant	17	3.22174861	6.81E-18	3.27200626
ACE	17:63486300	C/A	stop_gained	4	9.10262032	0.00107677	3.11768804
MSR1	8:16186158	C/T	splice_donor_variant& intron_variant	4	3.28217749	5.35E-04	0.73409481
COL6A2	21:46125455	A/AC	splice_acceptor_variant& intron_variant	1	3.28721175	7.06E-18	0.34946627
SIGLEC10	19:51417359	C/T	splice_acceptor_variant& intron_variant	2	1.88542826	1.09E-08	-0.0807563
RETSAT	2:85350974	TA/T	frameshift_variant	3	1.48768267	2.26E-04	-0.1410527
CC2D2A	4:15480736	C/T	stop_gained	1	1.84782388	4.07E-04	-0.4083765

305

307


## 308 **Dynamics of Gene Expression in Pre- and Post-Treatment Time Series**

The temporal changes in expression levels for selected genes were assessed. For each gene group, log2 fold changes were calculated at three time points: pre-treatment, 1 month, and 3 months post-treatment. Significant changes in expression levels were observed when comparing pre-treatment samples to those from healthy subjects, particularly for the genes ACE, CC2D2A, COL6A2, EPST11, IFI27, IFI44, MSR1, OAS2, RETSAT, and SIGLEC10 (Figure 2a). Overall, many genes exhibited significant temporal changes in expression levels compared to pre-treatment. For example, EPST11 was strongly upregulated before treatment, with this upregulation alleviated after one month and further reduced after three

<sup>306</sup> Table 7: Identification of Key Disease-Associated Genes Based on Z-Score Values

315months. A similar pattern was observed for IFI27, IFI44, and CC2D2A. Conversely, ACE and RETSAT exhibited a 316 reverse trend, with marked suppression of expression before and one month post-treatment, followed by recovery after 317 three months. PTPRJ and SIGLEC10 showed reduced expression at 1 and 3 months post-treatment compared to healthy 318subjects, while OR13C8 and SLC35G had a read count of 0 in both patients and healthy subjects. Enrichment analysis 319 revealed that GO terms related to the regulation of immune response, leukocyte-mediated immunity, and cell killing were 320 enriched in pre-treatment samples but were no longer enriched at 1 and 3 months post-treatment (Figure 2b). In contrast, 321GO terms involved in chemotaxis, cell migration, and cell differentiation were newly enriched at 1 and 3 months post-322treatment. The pre-treatment samples were plotted in the third quadrant, while the 1- and 3-month post-treatment samples 323were plotted in the first quadrant (Figure 2c). A heatmap identified genes with high loading on the negative axis of PC1, 324including BFAR, XG, RCE1, and COL18A1 (Figure 2d). For each gene showing a recovery trend after 3 months, the 325OMIM database was used to search for causative genes with phenotypes similar to those observed in the patient. The 326results indicated that a decrease in ACE led to an increase in bradykinin, contributing to the development of angioedema

327 [14,15].



330 Figure 2. Analysis of Time-Series Changes in Gene Expression Levels and Pathway Enrichment

Analysis of Changes in Gene Expression Levels and Enriched Pathways Using Patient Samples Collected at Pretreatment, 1 Month, and 3 Month Time Points. a) Comparison of expression levels of candidate target genes at each time point. Three asterisks indicate an adjusted p-value of less than 0.01, representing a significant difference from the healthy group. b) Transition of enriched GO terms at each time point, representing Biological Process (BP), Molecular Function (MF), and Cellular Component (CC). c) PCA plot using RNA-seq data from healthy subjects and patients at each time point. d) PCA for each gene. e) Heatmap displaying loading values, showing PC1 to PC5, clustered in rows.

337

## 338 Exploration of upstream and master regulators of the ACE gene by IPA

339 Analysis of the dynamics of gene expression in pre- and post-treatment time series suggested a relationship between the 340 ACE gene and patients with the disease. To further explore this, we investigated the relationship between the ACE gene 341 and the disease by visualizing upstream regulators and causal networks using IPA for the ACE gene. When we searched 342 for upstream regulators of ACE using pre-treatment RNA-seq data, we found that the IFNG gene had the highest 343 Activation z-score of 4.403 (Figure S5a). Similarly, in the causal network's Activation z-scores, the IFNG gene also had 344the highest Activation z-score of 4.217 (Figure S5b). The network visualization showed an interaction from IFNG in the 345extracellular space to ACE in the plasma membrane (Figure S5c). To further investigate the association between IFNG 346 and this patient, a drill-down analysis using IPA for the IFNG gene identified an association with idiopathic eosinophilia 347[16]. Pathways enriched in IPA for this disease, including pathway diagrams for RNA virus infection and network 348 diagrams for Angioedema, which are suggested to be relevant to the disease pathogenesis, are provided in the 349Supplementary Information (Figures S6, 7).

350

#### 351 Discussion

The aim of this study was to identify the pathological factors in patients diagnosed with HE/Gleich syndrome of unknown etiology using WGS and RNA-seq analysis.

The patient presented with clinical symptoms consistent with Gleich's syndrome, including marked eosinophilia exceeding  $5000/\mu$ L at its peak, periodic fever, and recurrent edema and urticaria. However, the patient also exhibited a generalized skin rash with pathological findings of vasculitis and pigmentation, transient neutrophil-predominant leukemoid reactions associated with fever, markedly elevated CRP levels, and splenomegaly. These findings are not commonly observed in Gleich's syndrome, but similar cases have been reported [17–19]. Although this patient did not meet the strict diagnostic criteria for HES, as eosinophilic infiltration was not clearly demonstrated in various organ

assessments, some consider Gleich syndrome itself to be a broader category of HES [20]. This reflects the fact that the disease concepts of HE and HES are not fully defined, and their classification has evolved over time. In any case, the patient exhibited a very advanced and dramatic clinical presentation, with no spontaneous remission for more than 6 months, leading to a diagnosis of severe Gleich syndrome after all other differential diagnoses were ruled out.

364Gleich syndrome is a rare disease with no currently approved or clearly defined diagnostic criteria, and to date, 365fewer than 100 adult cases have been reported [21]. Nevertheless, patients with Gleich syndrome typically present with 366 homogeneous clinical symptoms and well-characterized laboratory findings, suggesting that the disease should be 367 considered a distinct eosinophilic disorder, likely caused by a common pathogenic mechanism [19]. 368In cases with clear and intense symptoms, as in this case, even a small number of disease samples are likely to lead to the 369identification of some pathological factors by Multi-Omics Analysis, which is very significant for the purpose of 370 elucidating the pathology of rare diseases. This is very significant for the purpose of elucidating the pathology of rare 371diseases.

372 In the disease variant analysis using WGS data, deletion mutations associated with FOXO1, PRDM16, SPAST, 373 ITSN1, and DLGAP2 were identified in AnnotSV as variants with an ACMG class >3 and a LOEUF\_bin score of 0. The 374FOXO family, including FOXO1, is known to upregulate various pro-inflammatory cytokines, including interleukin (IL)-37516, IL-9, Toll-like receptor (TLR)1, and TLR4 [22]. FOXO1 is activated by bacteria in dendritic cells (DCs) and plays 376 crucial roles in immune responses, including promoting DC phagocytosis, migration, homing to lymph nodes, 377 stimulating T cells, activating B cells, and enhancing antibody production [23]. The PRDM16 gene regulates adipocyte 378 differentiation and thermogenesis, making it a promising target for the treatment of obesity and diabetes [24,25]. It is also 379involved in the development and function of endothelial cells and vascular smooth muscle cells in arteries and plays a 380 critical role in the regulation of inflammatory responses [26]. ITSN1 is known to play a crucial role in pathogen uptake 381through clathrin-mediated endocytosis (CME) and also functions as a scaffolding protein in cell signaling pathways [27]. 382This may allow ITSN1 to influence eosinophil activation and function.SPAST and DLGAP2 are both genes that are 383 critical for maintaining the health and function of the nervous system and have not been reported to be involved in 384 eosinophil-related diseases.

385

SNPnexus-based analysis identified PTPRJ, SLC4A1, FGFR4, and C1GALT1C1 as genes with corresponding

- 386 mutations classified as pathogenic in the ClinVar annotations. PTPRJ and FGFR4 are implicated in the development and
- susceptibility to various cancers [28–37]. Eosinophils are known to play an anti-tumor role in melanoma, gastric,
- 388 colorectal, oral, and prostate cancers, while they are associated with poor prognosis in Hodgkin's lymphoma and cervical

389 cancer [38]. The relationship between eosinophilia-associated SNPs and tumor grade warrants further investigation. 390 SLC4A1 (Solute Carrier Family 4 Member 1) encodes an anion exchange protein critical for erythrocyte function, and 391 mutations in SLC4A1 have been shown to impair erythrocyte membrane stability [39]. However, no involvement in 392eosinophil-related diseases has been reported to date. C1GALT1C1 is crucial for glycosylation, and patients with Tn 393 polyagglutination syndrome (TNPS) are known to carry an aspartic acid to glutamic acid mutation at position 131 [40]. 394 Confirmation of mutations by exon using wANNOVAR identified a series of mutations across diverse genes, 395including APC, OR13C8, PCDH17, GSPT1, MED1, SLC35G4, and MADCAM1. The APC gene has been associated 396 with familial colorectal adenomatosis, as documented on the ClinVar website [41]. PCDH17 is primarily involved in 397 neuronal adhesion and synapse formation [42]. GSPT1 is a gene implicated in cell proliferation and translation 398 regulation. MED1 functions as a transcriptional regulator in the nucleus, controlling the expression of specific genes 399 [43,44]. MADCAM1, a cell adhesion molecule, is expressed in high endothelial venules, facilitating immune cell 400 migration from the bloodstream to the gut [45]. However, no studies have been identified that directly link any of these

401 genes to eosinophilia.

402In the analysis of DEGs between patients and healthy controls from RNA-seq data, the Biological Process 403 category of GO term enrichment analysis showed enrichment in 'regulation of response to biotic stimulus,' 'response to 404 virus,' and GO terms related to 'regulation of viral processes.' Hypereosinophilia refers to an increase in the number of 405eosinophils in the blood, observed in response to various biotic stimuli such as infections, allergic reactions, viruses, and 406 certain autoimmune diseases [46–48]. Eosinophils are a type of white blood cell that plays a crucial role in the body's 407 immune response to parasites and allergens. Their regulation and proliferation are known to be influenced by various 408 cytokines and transcription factors, most notably interleukin-5 (IL-5) [49]. The identification of several genes enriched 409by biotic stimuli in this patient also reflects a pathology that results in a dramatic systemic clinical presentation.

410In addition, within the Molecular Function category, several GO terms were enriched for carbohydrate binding, 411 monosaccharide binding, glucose binding, proteoglycan binding, and glycan-related genes, such as 'pentosyltransferase 412 activity.' Glycosylation is a common post-translational modification of proteins and lipids and serves as a critical 413 recognition determinant in cell-immune system interactions. Immune and stromal cells are equipped with glycan-binding 414proteins (GBPs) that sense and decode diverse glycans [50,51]. This network of glycans and GBPs is crucial for the 415recognition of pathogens and the regulation of inflammatory and autoimmune responses, with alterations in the cellular 416 glycome ultimately leading to pathological phenotypes [52–54]. C1GALT1C1 (rs17261572), also known as Cosmc, 417 identified in variant analysis, galactosylates Tn antigen (GalNAcα1-Ser/Thr-R) during the biosynthesis of mucin-type O-

418 glycans to core 1 Gal $\beta$ 1-3GalNAc $\alpha$ 1-Ser/Thr (T antigen) [55] (Figure S8). Given that glycans function as drug 419 recognition markers, the potential involvement of glycan-related genes in drug regulation has been investigated in public 420 database analyses [56]. The relationship between rs17261572 on C1GALT1C1 and HE/Gleich syndrome, as well as its 421 connection to other glycan-related genes, warrants further investigation.

422The Z-score values derived from WGS annotation impact, along with the ranking of DEGs and PPI network 423analysis from RNA-seq data, identified IFI27, OAS2, and ACE as key candidate genes. In this case, the expression levels 424of these genes were variable compared to healthy subjects and showed a recovery trend after treatment. It is well 425established that a reduction in ACE leads to an increase in bradykinin, which contributes to the development of 426angioedema [57,58]. Bradykinin itself induces angioedema [59] and further increases phospholipase A2 activity, 427enhances arachidonic acid metabolism, and triggers a wide range of inflammatory responses [60]. Additionally, large 428amounts of bradykinin have been reported to recruit eosinophils [60,61]. In this patient, who presented with severe 429systemic inflammation in addition to edema, ACE was found to play a major role as a pathological factor. The patient 430 achieved a good state of remission with oral prednisolone treatment, not only due to the general anti-inflammatory effects 431of corticosteroids but also because corticosteroids have been suggested to directly restore ACE expression [62], which 432may have contributed to the improvement in the condition.

433 Notably, there is a case report of a patient with congenital ACE deficiency presenting with recurrent angioedema 434 [63]. This finding further supports the involvement of ACE as a pathological factor in diseases characterized by 435 angioedema (Figure 3). However, in the present case, no mutation in the ACE gene itself critically defines a loss of 436 expression, suggesting that an alteration in an upstream factor leading to reduced ACE expression may be involved.


PRDM16, a gene with a confirmed structural abnormality in this case, has been shown to reduce ACE mRNA expression in the systemic RAAS when conditionally knocked out (CKO) in the heart, although the detailed mechanism remains unclear [64]. While ACE expression in the intrarenal RAAS is compensated for in this CKO model, it is plausible that the PRDM16 mutation observed in this patient results in a systemic reduction in ACE expression. However, the direct mechanism by which PRDM16 mutations lead to reduced ACE expression is not fully understood and warrants further investigation.

443 Upstream regulators and causal networks of ACE were investigated using IPA to explore their relationship with 444 the pathogenesis in greater detail. The IFNG gene was identified as an upstream regulator of ACE. Previous studies have 445 reported that human IFNG protein increases the expression of ACE mRNA in NB4 cells and enhances the expression of 446 ACE protein on the cell surface of cultured human peripheral blood monocytes [65]. Additionally, IFNG has been

detected in the supernatant of cultured peripheral blood mononuclear cells from patients with idiopathic eosinophilia,
suggesting its involvement in the disease's pathogenesis [66]. Further research is needed to elucidate these mechanisms in
more detail.

450This study has certain limitations. While Multi-Omics analyses using whole genome sequencing (WGS) and 451RNA sequencing (RNA-seq) have advanced our understanding of the pathogenesis of HE/Gleich syndrome at the genetic 452and gene expression levels, these approaches must be supplemented with protein-level analyses and in vivo model-based 453studies. Confirming blood levels of bradykinin and ACE would further substantiate the pathogenesis of this condition. 454Moreover, other factors influencing ACE expression need to be investigated, and detailed mechanisms must be 455elucidated. Gene expression data alone do not adequately capture post-translational modifications, protein interactions, or 456functional dynamics within cells and tissues. In vivo models can provide a more comprehensive understanding of disease 457mechanisms within a physiological context. Therefore, future research should incorporate proteomic analyses, gene 458editing techniques, and animal models. 459





460

461 Figure 3 The role of ACE as a pathogenic factor in a type of HE/Gleich syndrome

462 This figure illustrates the pathway by which a PRDM16 mutation leads to pathogenic outcomes in HE/Gleich Syndrome.

463 The mutation downregulates ACE expression, resulting in elevated bradykinin levels. This triggers the arachidonic acid

464 cascade, which contributes to both angioedema and severe inflammation. Additionally, IFN-γ levels influence ACE

465 expression, further exacerbating these processes.

## 467 Conclusion

- The aim of this study was to analyze whole genome sequencing (WGS) and RNA sequencing (RNA-seq) data from patient-derived samples of individuals diagnosed with severe HE/Gleich syndrome of unknown etiology, and to identify the underlying pathological factors. The analysis revealed that ACE plays a significant role in the condition, demonstrating the utility of genomic analysis for understanding this disease. Specifically, the study indicated that reduced ACE expression may result from a complex interplay of factors, including PRDM16 gene mutations and altered expression of IFN $\gamma$ , which may contribute to the development of angioedema and marked inflammation. The findings of this study will enhance the understanding of the pathomechanisms of HE/Gleich syndrome and inform the development
- 475 of new therapeutic strategies in the future.

476	Supple	ementary Information
477		
478	Data A	wailability
479		
480	Ackno	wledgements
481	We sin	cerely thank the patients who participated in this study for their invaluable cooperation. I also wish to express our
482	deepes	t appreciation to Dr. Hirokazu Muraoka for his extensive guidance and support throughout the entirety of this
483	study.	His contributions spanned from the conceptualization of the research, the collection of blood samples, and the
484	acquis	ition of WGS and RNA-seq data, to the writing, editing, and discussion of the manuscript.
485		
486	Confli	ct of interest statement
487	The au	thors declare that there are no conflicts.
488		
489	Refere	ence
490	(1)	Roufosse, F.; Weller, P. F. Journal of Allergy and Clinical Immunology 2010, 126, 39-44.
491		doi:10.1016/j.jaci.2010.04.011
492	(2)	Rothenberg, M. E. New England Journal of Medicine 1998, 338, 1592–1600.
493		doi:10.1056/NEJM199805283382206
494	(3)	Valent, P.; Klion, A. D.; Horny, H. P.; Roufosse, F.; Gotlib, J.; Weller, P. F.; Hellmann, A.; Metzgeroth, G.;
495		Leiferman, K. M.; Arock, M.; Butterfield, J. H.; Sperr, W. R.; Sotlar, K.; Vandenberghe, P.; Haferlach, T.;
496		Simon, H. U.; Reiter, A.; Gleich, G. J. Journal of Allergy and Clinical Immunology 2012, 130, 607-612.e9.
497		doi:10.1016/j.jaci.2012.02.019
498	(4)	Gleich, G. J.; Schroeter, A. L.; Marcoux, J. P.; Sachs, M. I.; O'Connell, E. J.; Kohler, P. F. Trans Assoc Am
499		Physicians 1984, 97, 25-32. doi:10.1056/NEJM198406213102501
500	(5)	Cools, J.; DeAngelo, D. J.; Gotlib, J.; Stover, E. H.; Legare, R. D.; Cortes, J.; Kutok, J.; Clark, J.; Galinsky,
501		I.; Griffin, J. D.; Cross, N. C. P.; Tefferi, A.; Malone, J.; Alam, R.; Schrier, S. L.; Schmid, J.; Rose, M.;
502		Vandenberghe, P.; Verhoef, G.; Boogaerts, M.; Wlodarska, I.; Kantarjian, H.; Marynen, P.; Coutre, S. E.;
503		Stone, R.; Gilliland, D. G. New England Journal of Medicine 2003, 348, 1201–1214.

504 doi:10.1056/NEJMOA025217/ASSET/02DE2273-F36A-40F0-A786-
---

- 505 276BD835B728/ASSETS/IMAGES/LARGE/NEJMOA025217\_F5.JPG
- 506 (6) Simon, H.-U.; Plötz, S. G.; Dummer, R.; Blaser, K. New England Journal of Medicine 1999, 341, 1112–
   507 1120. doi:10.1056/NEJM199910073411503/ASSET/F1312766-756C-4DAD-BB7E-
- 508 B527821BB498/ASSETS/IMAGES/LARGE/NEJM199910073411503\_T4.JPG
- 509 (7) Van El, C. G.; Cornel, M. C.; Borry, P.; Hastings, R. J.; Fellmann, F.; Hodgson, S. V.; Howard, H. C.;
- 510 Cambon-Thomsen, A.; Knoppers, B. M.; Meijers-Heijboer, H.; Scheffer, H.; Tranebjaerg, L.; Dondorp, W.;
- 511 De Wert, G. M. W. R. European Journal of Human Genetics 2013 21:6 2013, 21, 580–584. 512 doi:10.1038/ejhg.2013.46
- 513 (8) Ashley, E. A.; Butte, A. J.; Wheeler, M. T.; Chen, R.; Klein, T. E.; Dewey, F. E.; Dudley, J. T.; Ormond, K.
- 514 E.; Pavlovic, A.; Morgan, A. A.; Pushkarev, D.; Neff, N. F.; Hudgins, L.; Gong, L.; Hodges, L. M.; Berlin,
- 515 D. S.; Thorn, C. F.; Sangkuhl, K.; Hebert, J. M.; Woon, M.; Sagreiya, H.; Whaley, R.; Knowles, J. W.;
- 516 Chou, M. F.; Thakuria, J. V.; Rosenbaum, A. M.; Zaranek, A. W.; Church, G. M.; Greely, H. T.; Quake, S.

517 R.; Altman, R. B. *The Lancet* **2010**, *375*, 1525–1535. doi:10.1016/S0140-6736(10)60452-7

- 518 (9) Lupski, J. R.; Reid, J. G.; Gonzaga-Jauregui, C.; Rio Deiros, D.; Chen, D. C. Y.; Nazareth, L.; Bainbridge,
- 519 M.; Dinh, H.; Jing, C.; Wheeler, D. A.; McGuire, A. L.; Zhang, F.; Stankiewicz, P.; Halperin, J. J.; Yang, C.;
- 520 Gehman, C.; Guo, D.; Irikat, R. K.; Tom, W.; Fantin, N. J.; Muzny, D. M.; Gibbs, R. A. New England
- 521 Journal of Medicine **2010**, 362, 1181–1191.
- 522 doi:10.1056/NEJMOA0908094/SUPPL\_FILE/NEJMOA0908094\_DISCLOSURES.PDF
- 523 (10) Roach, J. C.; Glusman, G.; Smit, A. F. A.; Huff, C. D.; Hubley, R.; Shannon, P. T.; Rowen, L.; Pant, K. P.;
- 524 Goodman, N.; Bamshad, M.; Shendure, J.; Drmanac, R.; Jorde, L. B.; Hood, L.; Galas, D. J. Science (1979)

525 **2010**, *328*, 636–639. doi:10.1126/SCIENCE.1186802/SUPPL\_FILE/ROACH-SOM.PDF

- 526 (11) Lee, J. S.; Seo, H.; Im, K.; Park, S. N.; Kim, S. M.; Lee, E. K.; Kim, J. A.; Lee, J. H.; Kwon, S.; Kim, M.;
- 527 Koh, I.; Hwang, S.; Park, H. W.; Kang, H. R.; Park, K. S.; Kim, J. H.; Lee, D. S. *PLoS One* 2017, *12*,
  528 e0185602. doi:10.1371/JOURNAL.PONE.0185602
- Andersen, C. L.; Nielsen, H. M.; Kristensen, L. S.; Søgaard, A.; Vikeså, J.; Jønson, L.; Nielsen, F. C.;
  Hasselbalch, H.; Bjerrum, O. W.; Punj, V.; Grønbæk, K.; Andersen, C. L.; Nielsen, H. M.; Kristensen, L. S.;

- 531 Søgaard, A.; Vikeså, J.; Jønson, L.; Nielsen, F. C.; Hasselbalch, H.; Bjerrum, O. W.; Punj, V.; Grønbæk, K.
- 532 Oncotarget **2015**, *6*, 40588–40597. doi:10.18632/ONCOTARGET.5845
- 533 (13) Blake, J. A.; Christie, K. R.; Dolan, M. E.; Drabkin, H. J.; Hill, D. P.; Ni, L.; Sitnikov, D.; Burgess, S.;
- 534 Buza, T.; Gresham, C.; McCarthy, F.; Pillai, L.; Wang, H.; Carbon, S.; Dietze, H.; Lewis, S. E.; Mungall, C.
- 535 J.; Munoz-Torres, M. C.; Feuermann, M.; Gaudet, P.; Basu, S.; Chisholm, R. L.; Dodson, R. J.; Fey, P.; Mi,
- 536 H.; Thomas, P. D.; Muruganujan, A.; Poudel, S.; Hu, J. C.; Aleksander, S. A.; McIntosh, B. K.; Renfro, D.
- 537 P.; Siegele, D. A.; Attrill, H.; Brown, N. H.; Tweedie, S.; Lomax, J.; Osumi-Sutherland, D.; Parkinson, H.;
- 538 Roncaglia, P.; Lovering, R. C.; Talmud, P. J.; Humphries, S. E.; Denny, P.; Campbell, N. H.; Foulger, R. E.;
- 539 Chibucos, M. C.; Giglio, M. G.; Chang, H. Y.; Finn, R.; Fraser, M.; Mitchell, A.; Nuka, G.; Pesseat, S.;
- 540 Sangrador, A.; Scheremetjew, M.; Young, S. Y.; Stephan, R.; Harris, M. A.; Oliver, S. G.; Rutherford, K.;
- 541 Wood, V.; Bahler, J.; Lock, A.; Kersey, P. J.; McDowall, M. D.; Staines, D. M.; Dwinell, M.; Shimoyama,
- 542 M.; Laulederkind, S.; Hayman, G. T.; Wang, S. J.; Petri, V.; D'Eustachio, P.; Matthews, L.; Balakrishnan,
- 543 R.; Binkley, G.; Cherry, J. M.; Costanzo, M. C.; Demeter, J.; Dwight, S. S.; Engel, S. R.; Hitz, B. C.; Inglis,
- 544 D. O.; Lloyd, P.; Miyasato, S. R.; Paskov, K.; Roe, G.; Simison, M.; Nash, R. S.; Skrzypek, M. S.; Weng, S.;
- 545 Wong, E. D.; Berardini, T. Z.; Li, D.; Huala, E.; Argasinska, J.; Arighi, C.; Auchincloss, A.; Axelsen, K.;
- 546 Argoud-Puy, G.; Bateman, A.; Bely, B.; Blatter, M. C.; Bonilla, C.; Bougueleret, L.; Boutet, E.; Breuza, L.;
- 547 Bridge, A.; Britto, R.; Casals, C.; Cibrian-Uhalte, E.; Coudert, E.; Cusin, I.; Duek-Roggli, P.; Estreicher, A.;
- 548 Famiglietti, L.; Gane, P.; Garmiri, P.; Gos, A.; Gruaz-Gumowski, N.; Hatton-Ellis, E.; Hinz, U.; Hulo, C.;
- 549 Huntley, R.; Jungo, F.; Keller, G.; Laiho, K.; Lemercier, P.; Lieberherr, D.; Macdougall, A.; Magrane, M.;
- 550 Martin, M.; Masson, P.; Mutowo, P.; O'Donovan, C.; Pedruzzi, I.; Pichler, K.; Poggioli, D.; Poux, S.;
- 551 Rivoire, C.; Roechert, B.; Sawford, T.; Schneider, M.; Shypitsyna, A.; Stutz, A.; Sundaram, S.; Tognolli, M.;
- 552 Wu, C.; Xenarios, I.; Chan, J.; Kishore, R.; Sternberg, P. W.; Van Auken, K.; Muller, H. M.; Done, J.; Li, Y.;
- 553 Howe, D.; Westerfeld, M. Nucleic Acids Res 2015, 43, D1049–D1056. doi:10.1093/NAR/GKU1179
- 554 (14) Ghebrehiwet, B.; Joseph, K.; Kaplan, A. P. Frontiers in Allergy 2024, 5, 1302605.
   555 doi:10.3389/FALGY.2024.1302605/BIBTEX
- 556 (15) Straka, B. T.; Ramirez, C. E.; Byrd, J. B.; Stone, E.; Woodard-Grice, A.; Nian, H.; Yu, C.; Banerji, A.;
  557 Brown, N. J. *Journal of Allergy and Clinical Immunology* 2017, *140*, 242-248.e2.
  558 doi:10.1016/j.jaci.2016.09.051

- 559 (16) Simon, H.-U.; Plötz, S. G.; Dummer, R.; Blaser, K. New England Journal of Medicine 1999, 341, 1112–
- 560 1120. doi:10.1056/NEJM199910073411503/ASSET/F1312766-756C-4DAD-BB7E-
- 561 B527821BB498/ASSETS/IMAGES/LARGE/NEJM199910073411503\_T4.JPG
- 562 (17) Basso, J. R.; Bizinoto, L. G. Z.; Limone, G. A.; Enokihara, M. M. S. S.; Do Espirito-Santo Filho, K.;
- 563 Fonseca, A. R.; Agondi, R. C.; de Gois, A. F. T.; Cunha, L. L. Brazilian Journal of Medical and Biological
- 564 *Research* **2021**, *54*, e10745. doi:10.1590/1414-431X202010745
- 565 (18) Mormile, I.; Petraroli, A.; Loffredo, S.; Rossi, F. W.; Mormile, M.; Mastro, A. Del; Spadaro, G.; de Paulis,
- 566 A.; Bova, M. Journal of Clinical Medicine 2021, Vol. 10, Page 1442 2021, 10, 1442.
  567 doi:10.3390/JCM10071442
- 568 (19) Khoury, P.; Herold, A.; Alpaugh, A.; Dinerman, E.; Holland-Thomas, N.; Stoddard, J.; Gurprasad, S.; Maric,
- 569 I.; Simakova, O.; Schwartz, L. B.; Fong, J.; Richard Lee, C. C.; Xi, L.; Wang, Z.; Raffeld, M.; Klion, A. D.
- 570 *Haematologica* **2015**, *100*, 300–307. doi:10.3324/HAEMATOL.2013.091264
- 571 (20) Valent, P.; Klion, A. D.; Horny, H. P.; Roufosse, F.; Gotlib, J.; Weller, P. F.; Hellmann, A.; Metzgeroth, G.;
- 572 Leiferman, K. M.; Arock, M.; Butterfield, J. H.; Sperr, W. R.; Sotlar, K.; Vandenberghe, P.; Haferlach, T.;
- 573 Simon, H. U.; Reiter, A.; Gleich, G. J. Journal of Allergy and Clinical Immunology **2012**, 130, 607-612.e9.
- 574 doi:10.1016/j.jaci.2012.02.019
- 575 (21) Mormile, I.; Petraroli, A.; Loffredo, S.; Rossi, F. W.; Mormile, M.; Mastro, A. Del; Spadaro, G.; de Paulis,
  576 A.; Bova, M. *Journal of Clinical Medicine 2021, Vol. 10, Page 1442* 2021, *10*, 1442.
  577 doi:10.3390/JCM10071442
- 578 (22) Kim, M. E.; Kim, D. H.; Lee, J. S. International Journal of Molecular Sciences 2022, Vol. 23, Page 11877
   579 2022, 23, 11877. doi:10.3390/IJMS231911877
- (23) Cabrera-Ortega, A. A.; Feinberg, D.; Liang, Y.; Rossa, C.; Graves, D. T. Critical Reviews™ in
   *Immunology* 2017, 37, 1–13. doi:10.1615/CRITREVIMMUNOL.2017019636
- 582 (24) Seale, P.; Conroe, H. M.; Estall, J.; Kajimura, S.; Frontini, A.; Ishibashi, J.; Cohen, P.; Cinti, S.; Spiegelman,
  583 B. M. *J Clin Invest* 2011, *121*, 96–105. doi:10.1172/JCI44271
- 584 (25) Jiang, N.; Yang, M.; Han, Y.; Zhao, H.; Sun, L. Front Pharmacol 2022, 13, 870250.
   585 doi:10.3389/FPHAR.2022.870250/BIBTEX


- 586 (26) Thompson, M.; Sakabe, M.; Verba, M.; Hao, J.; Meadows, S. M.; Lu, Q. R.; Xin, M. Front Physiol 2023,
- 587 *14*, 1165379. doi:10.3389/FPHYS.2023.1165379/BIBTEX
- 588 (27) Gerasymchuk, D.; Hubiernatorova, A.; Domanskyi, A. *Front Neurol* 2020, *11*, 549006.
   589 doi:10.3389/FNEUR.2020.549006/BIBTEX
- 590 (28) Iuliano, R.; Le Pera, I.; Cristofaro, C.; Baudi, F.; Arturi, F.; Pallante, P. L.; Martelli, M. L.; Trapasso, F.;
- 591 Chiariotti, L.; Fusco, A. Oncogene 2004 23:52 2004, 23, 8432–8438. doi:10.1038/sj.onc.1207766
- 592 (29) Jaakkola, S.; Salmikangas, P.; Nylund, S.; Lehtovirta, P.; Nevanlinna, H.; Partanen, J.; Armstrong, E.;
   593 Pyrhönen, S. *Int J Cancer* 1993, *54*, 378–382. doi:10.1002/IJC.2910540305
- 594 (30) Leung, H. Y.; Gullick, W. J.; Lemoine, N. R. Int J Cancer 1994, 59, 667–675. doi:10.1002/IJC.2910590515
- 595 (31) Sahadevan, K.; Darby, S.; Leung, H. Y.; Mathers, M. E.; Robson, C. N.; Gnanapragasam, V. J. J Pathol
  596 2007, 213, 82–90. doi:10.1002/PATH.2205
- 597 (32) Streit, S.; Mestel, D. S.; Schmidt, M.; Ullrich, A.; Berking, C. *British Journal of Cancer 2006 94:12* 2006,
  598 94, 1879–1886. doi:10.1038/sj.bjc.6603181
- 599 (33) Cancer Progression and Tumor Cell Motility Are Associated with the FGFR4 Arg388 Allele | Cancer
- 600 Research American Association for Cancer Research
- 601 https://aacrjournals.org/cancerres/article/62/3/840/509605/Cancer-Progression-and-Tumor-Cell-Motility-
- 602 Are (accessed Aug 16, 2024)
- 603 (34) Matakidou, A.; El Galta, R.; Rudd, M. F.; Webb, E. L.; Bridle, H.; Eisen, T.; Houlston, R. S. *British Journal* 604 of *Cancer 2007 96:12* 2007, *96*, 1904–1907. doi:10.1038/sj.bjc.6603816
- 605 (35) Spinola, M.; Leani, V.; Pignatiello, C.; Conti, B.; Ravagnani, F.; Pastorino, U.; Dragani, T. A.
   606 https://doi.org/10.1200/JCO.2005.17.350 2016, 23, 7307–7311. doi:10.1200/JCO.2005.17.350
- 607 (36) Wang, J.; Stockton, D. W.; Ittmann, M. *Clinical Cancer Research* 2004, *10*, 6169–6178. doi:10.1158/1078 608 0432.CCR-04-0408
- 609 (37) Thussbas, C.; Nahrig, J.; Streit, S.; Bange, J.; Kriner, M.; Kates, R.; Ulm, K.; Kiechle, M.; Hoefler, H.;
- 610 Ullrich, A.; Harbeck, N. *https://doi.org/10.1200/JCO.2005.04.8587* 2016, 24, 3747–3755.
  611 doi:10.1200/JCO.2005.04.8587
- (38) Varricchi, G.; Galdiero, M. R.; Loffredo, S.; Lucarini, V.; Marone, G.; Mattei, F.; Marone, G.; Schiavoni, G.
   *Oncoimmunology* 2018, 7. doi:10.1080/2162402X.2017.1393134


- 614 (39) Bruce, L. J.; Robinson, H. C.; Guizouarn, H.; Borgese, F.; Harrison, P.; King, M. J.; Goede, J. S.; Coles, S.
- E.; Gore, D. M.; Lutz, H. U.; Ficarella, R.; Layton, D. M.; Iolascon, A.; Ellory, J. C.; Stewart, G. W. Nature
- 616 *Genetics 2005 37:11* **2005**, *37*, 1258–1263. doi:10.1038/ng1656
- 617 (40) Ju, T.; Cummings, R. D. Proc Natl Acad Sci U S A 2002, 99, 16613–16618.
- 618 doi:10.1073/PNAS.262438199/ASSET/E7D75E83-13F7-4461-A8AA-
- 619 B2B085A2E14B/ASSETS/GRAPHIC/PQ2624381004.JPEG
- 620 (41) VCV001050412.3 ClinVar NCBI https://www.ncbi.nlm.nih.gov/clinvar/variation/1050412/ (accessed
  621 Aug 16, 2024)
- 622 (42) Abrahams, B. S.; Tentler, D.; Perederiy, J. V.; Oldham, M. C.; Coppola, G.; Geschwind, D. H. Proc Natl
- 623
   Acad
   Sci
   U
   S
   A
   2007,
   104,
   17849–17854.

   624
   doi:10.1073/PNAS.0706128104/SUPPL\_FILE/06128TABLE6.PDF
- (43) Hoshino, S.; Imai, M.; Mizutani, M.; Kikuchi, Y.; Hanaoka, F.; Ui, M.; Katada, T. *Journal of Biological Chemistry* 1998, 273, 22254–22259. doi:10.1074/jbc.273.35.22254
- 627 (44) Kikuchi, Y.; Shimatake, H.; Kikuchi, A. *EMBO J* 1988, 7, 1175–1182. doi:10.1002/J.1460628 2075.1988.TB02928.X
- 629 (45) Arihiro, S.; Ohtani, H.; Suzuki, M.; Murata, M.; Ejima, C.; Oki, M.; Kinouchi, Y.; Fukushima, K.; Sasaki,
- 630 I.; Nakamura, S.; Matsumoto, T.; Torii, A.; Toda, G.; Nagura, H. *Pathol Int* 2002, *52*, 367–374.
  631 doi:10.1046/J.1440-1827.2002.01365.X
- (46) Macchia, I.; La Sorsa, V.; Urbani, F.; Moretti, S.; Antonucci, C.; Afferni, C.; Schiavoni, G. *Front Immunol*2023, *14*, 1170035. doi:10.3389/FIMMU.2023.1170035/BIBTEX
- 634 (47) Thomsen, G. N.; Christoffersen, M. N.; Lindegaard, H. M.; Davidsen, J. R.; Hartmeyer, G. N.; Assing, K.;
- 635 Mortz, C. G.; Martin-Iguacel, R.; Møller, M. B.; Kjeldsen, A. D.; Havelund, T.; El Fassi, D.; Broesby-
- 636 Olsen, S.; Maiborg, M.; Johansson, S. L.; Andersen, C. L.; Vestergaard, H.; Bjerrum, O. W. Front Oncol
- 637 **2023**, *13*, 1193730. doi:10.3389/FONC.2023.1193730/BIBTEX
- 638 (48) Klion, A. D. *Hematology* **2015**, *2015*, 92–97. doi:10.1182/ASHEDUCATION-2015.1.92
- 639 (49) Kouro, T.; Takatsu, K. Int Immunol 2009, 21, 1303–1309. doi:10.1093/INTIMM/DXP102
- 640 (50) Alves, I.; Fernandes, Â.; Santos-Pereira, B.; Azevedo, C. M.; Pinho, S. S. *FEBS Lett* **2022**, *596*, 1485–1502.
- 641 doi:10.1002/1873-3468.14347


- 642 (51) Pinho, S. S.; Alves, I.; Gaifem, J.; Rabinovich, G. A. Cellular & Molecular Immunology 2023 20:10 2023,
- 643 20, 1101–1113. doi:10.1038/s41423-023-01074-1
- 644 (52) Ohtsubo, K.; Marth, J. D. Cell 2006, 126, 855–867. doi:10.1016/J.CELL.2006.08.019
- 645 (53) Pinho, S. S.; Reis, C. A. Nature Reviews Cancer 2015 15:9 2015, 15, 540–555. doi:10.1038/nrc3982
- 646 (54) Rabinovich, G. A.; Croci, D. O. Immunity 2012, 36, 322–335. doi:10.1016/J.IMMUNI.2012.03.004
- 647 (55) Wang, Y.; Ju, T.; Ding, X.; Xia, B.; Wang, W.; Xia, L.; He, M.; Cummings, R. D. *Proc Natl Acad Sci U S A*648 2010, *107*, 9228–9233. doi:10.1073/PNAS.0914004107/SUPPL\_FILE/SFIG05.TIF
- 649 (56) Koreeda, T.; Honda, H. *Glycoconj J* **2024**, *41*, 133–149. doi:10.1007/S10719-024-10153-Y/METRICS
- 650 (57) Ghebrehiwet, B.; Joseph, K.; Kaplan, A. P. Frontiers in Allergy 2024, 5, 1302605.
  651 doi:10.3389/FALGY.2024.1302605/BIBTEX
- (58) Straka, B. T.; Ramirez, C. E.; Byrd, J. B.; Stone, E.; Woodard-Grice, A.; Nian, H.; Yu, C.; Banerji, A.;
  Brown, N. J. *Journal of Allergy and Clinical Immunology* 2017, *140*, 242-248.e2.
  doi:10.1016/j.jaci.2016.09.051
- 655 (59) Cicardi, M.; Zuraw, B. L. J Allergy Clin Immunol Pract 2018, 6, 1132–1141.
   656 doi:10.1016/J.JAIP.2018.04.022
- (60) Kaplan, A. P.; Joseph, K.; Silverberg, M. *Journal of Allergy and Clinical Immunology* 2002, *109*, 195–209.
   doi:10.1067/MAI.2002.121316
- 659 (61) Roisman, G. L.; Lacronique, J. G.; Desmazes-Dufeu, N.; Carré, C.; Le Cae, A.; Dusser, D. J.
   660 https://doi.org/10.1164/ajrccm.153.1.8542147 2012, 153, 381–390. doi:10.1164/AJRCCM.153.1.8542147
- 661 (62) Fishel, R. S.; Eisenberg, S.; Shai, S. Y.; Redden, R. A.; Bernstein, K. E.; Berk, B. C. *Hypertension* 1995, 25,
   662 343–349. doi:10.1161/01.HYP.25.3.343/ASSET/9C5DA6FC-13D9-494B-97A2-
- 663 3A87C146FD08/ASSETS/GRAPHIC/HY0350384008.JPEG
- 664 (63) Sreeram, A. B.; Corey, J. P. *http://dx.doi.org/10.1016/S0194-59989570277-6* 1995, *112*, 421–423.
  665 doi:10.1016/S0194-59989570277-6
- 666 (64) Kang, J. O.; Ha, T. W.; Jung, H. U.; Lim, J. E.; Oh, B. *PLoS One* 2022, *17*, e0267938.
  667 doi:10.1371/JOURNAL.PONE.0267938
- 668 (65) Obeid, D.; Nguyen, J.; Lesavre, P.; Bauvois, B. Oncogene 2007 26:1 2006, 26, 102–110.
  669 doi:10.1038/sj.onc.1209779


- 670 (66) Simon, H.-U.; Plötz, S. G.; Dummer, R.; Blaser, K. New England Journal of Medicine 1999, 341, 1112-
- 671 1120. doi:10.1056/NEJM199910073411503/ASSET/F1312766-756C-4DAD-BB7E-
- 672 B527821BB498/ASSETS/IMAGES/LARGE/NEJM199910073411503\_T4.JPG





PRDM16↓(mutation)





pre\_treatment one\_month three\_month Time Point